Biomarker Analysis for Patients With Metastatic Colorectal Cancer (MCC)

This is a short-term, prospective, feasibility study to determine how effectively investigators can obtain biomarker analysis on patients with mCRC from whom informed consent and authorization will be obtained. The study will be done in partnership with Quintiles. Investigators will be collecting data on the number of clinically actionable biomarkers that can be detected in each population and the number of trial actionable markers that can be detected in these populations. Patients with recurrent metastatic disease (ie, first diagnosis of metastatic disease following resection, last radiation, or last chemotherapy in the adjuvant setting) will have their primary specimen sent for a biomarker analysis. Actionable markers or genomic alterations will be FDA-approved companion diagnostic markers and markers used for trial enrollment in metastatic colorectal cancer. Additional information regarding FDA-approved companion diagnostic markers and markers used for trial enrollment in indications other than mCRC will also be collected and reported.

Biospecimens from 25 patients who have had early recurrence (≤ 12 months) and 25 patients who have had late recurrence (> 12 months) of their metastatic colorectal cancer will be appropriately collected, processed, shipped, and tested. The frequency and sites of mutation may be hypothesis generating to help identify those patients at higher risk for early recurrence and aid in identifying future treatment options and in selecting better treatment options for this poor prognostic group.

REGISTRATION PROCEDURES Written documentation of full, noncontingent IRB approval must be on file before a patient can be registered. The registration process begins when the coordinator has obtained a signed informed con-sent. Patient demographics will be into the Clinical Trial Management System (CTMS); this is the Web-based intranet system for the delivery of trial information across USOR. A unique patient number (UPN) will be assigned to the patient at that time. Entering a patient into CTMS does not signify that the patient has been registered in the study.

Once the patient has a UPN number, the coordinator can go to the Patient Report and select the patient to be registered. Located to the left of the patient's UPN will be the letters "Reg" in blue. The coordinator will click on the blue "Reg" to open up that patient's information. Each page that needs to be completed will be in yellow. The site will answer the questions on the Inclusions, Exclusions, and Prestudy Assessment pages. Once all questions on each page are answered, that page will turn green. An ID number and study arm will be directly assigned.

SAMPLE PROCUREMENT PROCEDURES USOR study sites will be supplied with tumor collection kits through the US Oncology Investigational Product Center (IPC).

Biospecimens will have a date of shipment within 4 weeks of the patient signing the consent in order to be enrolled in the study. Tissue will be sent to a central laboratory. Details for shipping will be provided in the Clinical Trials Information (CTI) provided separately by USOR.

Reference laboratory manual for tissue preparation and shipment instructions.

SAMPLE ANALYSIS AND CONFIDENTIALITY It is the intention of USOR and Quintiles that patient confidentiality will be maintained throughout the procedure. USOR maintains rigorous standards of confidentiality for clinical studies by coding samples with patient initials and a unique identifier (UPN number/patient/study ID number) and study number. A patient is in screening upon signing the ICF and registered in CTMS. A patient will be considered enrolled in the study if a standard of care biospecimen is available for biomarker testing with a shipment date within 4 weeks of ICF signature. If a standard of care biospecimen is unavailable, for any reason, within 4 weeks the patient is deemed a screen failure.

BIOSPECIMEN ASSESSMENT High throughput sequencing utilizing the Life Technologies Ion Torrent platform or similar alternative will be used. This methodology provides high-quality deep sequencing coverage ideally suited for SNP detection and mutational analysis. Point mutation identification analysis will include targeted whole exome sequencing of tumor tissue that will cover several hundred human protein-coding exons. Results from the profiling will be compiled and arranged according to relevancy to clinical practice. All clinically actionable results will be provided back to the physician using the same identifiers referenced above.

SAMPLE TESTING FAILURES Samples submitted for analysis will be from archived FFPE tissue. Ability to perform the AmpliSeq testing may be limited based on the quality and quantity of the sample available. Reasons for testing failures may be due to an inability to extract sufficient quality and quantity of DNA, inability to create a sequencing library or inability for a sample to sequence. Should a testing failure occur, the reason for the testing failure will be recorded by the laboratory and reported back to the clinician. A patient will have the opportunity, in discussion with their study physician, dependent on space in the study and approval from the US Oncology Clinical Project Manager, be allowed to re-submit one additional sample for sequencing. If a sample from a patient is a testing failure after 2 testing attempts, the patient is considered a permanent testing failure and will not be offered an opportunity to submit any additional samples.